Close Menu

NEW YORK – Exact Sciences reported after the close of the market on Tuesday that its third quarter revenues rose 85 percent year over year, thanks to an 89 percent increase in testing volumes for its Cologuard colorectal cancer screening test.

For the three months ended Sept. 30, the Madison, Wisconsin-based molecular diagnostics company reported revenues of $218.8 million, up from $118.3 million a year earlier, and beating the average Wall Street analyst estimate of $216.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.